OOIR: Observatory of International Research

Papers

(The H4-Index of mAbs is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries	296
Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms	227
Development of a novel, high-throughput imaged capillary isoelectric focusing-Western method to characterize charge heterogeneity of monoclonal antibody heavy and light chains	130
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability	110
In silico prediction of post-translational modifications in therapeutic antibodies	97
Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screening	89
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	74
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex	73
Phenotypic whole-cell screening identifies a protective carbohydrate epitope on Klebsiella pneumoniae	64
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma	63
Correction	62
An antibody developability triaging pipeline exploiting protein language models	61
Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning	59
Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn	53
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies	48
Correction	43
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	42
A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies	42
In-line product quality monitoring during biopharmaceutical manufacturing using computational Raman spectroscopy	40
Structural and functional characterization of a monoclonal antibody blocking TIGIT	38
Correction	38
Mitochondrial membrane potential-enriched CHO host: a novel and powerful tool for improving biomanufacturing capability	38
The proximity of the N- and C- termini of bovine knob domains enable engineering of target specificity into polypeptide chains	37
GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery	36
Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products	35

The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics	35
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs	34
Impact of IgG subclass on monoclonal antibody developability	34
Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy	31
Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity	31
A mouse pancreatic organoid model to compare PD-L1 blocking antibodies	30